T-DXd plus hormone therapy for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called T-DXd (a targeted chemotherapy) combined with hormone therapy for people with HER2-positive and hormone receptor-positive advanced breast cancer who have not had prior treatment for their metastatic disease. It includes an upfront phase, a maintenance phase, and a retreatment phase to see if restarting T-DXd is effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be HER2-positive and hormone receptor-positive (ER+ and/or PR+), and it must be advanced or spread (metastatic) and cannot be removed with surgery.
- You cannot have had any chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer before joining.
- If you had early-stage breast cancer treatment (like chemo or HER2 therapy), it must have been more than 6 months ago before your cancer came back as advanced.
- You must be in good enough physical condition to have a performance status of 0 or 1 (able to do daily activities).
- You must have at least one tumor that can be measured on scans, or only bone disease that can be followed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.